 |  |  |
Dear colleagues,
The CX Symposium team has made the difficult but necessary decision to cancel the Charing Cross Symposium 2020 that was scheduled to take place from 21 to 24 April in London, UK. We will be refunding in full all the registration fees incurred by delegates and will work with our Faculty members to assist […]
Industry leaders say approximately 50% of all medical devices will be withdrawn from the market; around 30% of manufacturers will not survive and patients might be at risk as a result of the European Medical Device Regulation (EU MDR), which is described by some as the “most disruptive force […]
Recorded presentation from CX Symposium 2019
Hence Verhagen, Rotterdam, Netherlands
Recorded presentation from CX Symposium 2019
Bijan Modarai, London, United Kingdom
Recorded presentation from CX Symposium 2019
Marc Schermerhorn, Boston, United States
In this interview, Meryl Davis, chair of the CX Abstract Board, talks about the benefits of presenting research at the CX Symposium and the importance of CX as a “global village”.
The CX Abstract Board is calling for senior and trainee doctors in the vascular and endovascular field to submit their […]
In addition to the plethora of late-breaking trials that were unveiled at this year’s Symposium, there was a vast array of Podium 1st presentations. These presentations showcased novel techniques and technologies, provided further insights into the safety and effectiveness of established devices, and highlighted potential solutions to current challenges in the management of vascular disease.
This year’s CX welcomed more than 4,000 participants at Olympia London from a record-breaking 86 countries.
A leader of innovation, CX 2018 hosted a record-breaking 71 exhibitors and 15 new product launches—similar numbers are expected for CX 2019.
See the full stats and highlights in the video above.
Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
Ulf Teichgräber, Jena, Germany
EVAS is associated with a reduction in all-cause mortality
Marc Schermerhorn, Boston, United States
Podium 1st: Lutonix AV IDE interim 24 month update
Kate Steiner, Stevenage, United Kingdom
Alun Davies, EVRA chief investigator
Imperial College, London, United Kingdom
Lowell Kabnick (New York, United States), who is a CX Faculty member, describes how the CX Venous Workshop has gone from being a small intimate session to one that, while still intimate, is “really large and all inclusive”. He adds that he believes that it is the best he has seen.
[…]
The CX Venous Consensus Update—Plenary Programme took place on the first day of CX 2017 (Tuesday, 25 April). Stephen Black, member of the CX Programme Organising Board, summarises the take-home messages of this session.
Pasha Normahani (Imperial Vascular Unit, Imperial Academic Health Science Centre, London, UK) has been an attendee at the Charing Cross (CX) Symposium for over seven years. In 2016, he presented for the first time at the CX Abstract sessions and was awarded with a Certificate of Merit for his research in peripheral arterial disease. In […]
Ian Loftus, Co-chairman CX Abstract Board, reviews the highlights of this year’s CX Abstract Presentations session. He emphasises the quality of the work submitted and how relevant it is for young and senior clinicians to present their research at the Charing Cross Symposium.
“The Peripheral Arterial Programme at the Charing Cross Symposium in 2016 is really exciting; it combines the hot topics in the field with evidence, opinion and discussion,” says Andrew Holden (Auckland, New Zealand), member of the CX Programme Organising Board. He overviews key areas to be discussed on Tuesday 26 April including the management of […]
In 2016, the Charing Cross Venous Programme will run on the four days of the Symposium (26–29 April) with the Main Programme for the first time on day 1, followed by the CX Venous Workshop on days 2 and 3, and the CX Venous Abstract Presentations on day 4. Ian Franklin (London, UK), member of […]
Stephen Black (London, UK), member of the CX Programme Organising Board, discusses the highlights of this year’s Deep Venous section of the CX Venous Challenges Day.
“There has never been a more exciting expectation of what we have for this year in the aortic area at CX,” says Roger Greenhalgh, chairman of the CX Programme Organising Board. Results from the Individual Patient Data meta-analysis of the four randomised controlled trials on endovascular aneurysm repair against open repair (EVAR 1, DREAM, OVER […]
Ian Franklin, a member of the CX Programme Organising Board and director of the CX Venous Workshop, speaks about new technologies for the treatment of varicose veins and about how deep venous interventions have been incorporated to the CX Venous Workshop.
Janet Powell, Imperial College, London, UK, is interviewed about the 12-month results of the IMPROVE trial, presented for the first time at CX 2015. The study compares open repair and an endovascular strategy for ruptured abdominal aortic aneurysms.
Colin Bicknell, London, UK, interviews Michael Dake, Stanford, USA, discussing the use of, and early results for, the new GORE TAG Thoracic Branch Endoprosthesis device.